CAN-1012

N/A

Report date: 2026/05/02 20:00:18
NME

Base Information

Drug NameCAN-1012
Drug Alias NameCAN-1012
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionToll like receptor 7 agonists
TargetsToll like receptor 7
Therapy Area/IndicationsSolid tumoursBreast Carcinoma In SituCarcinoma, Intraductal, Noninfiltrating +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCanWell Pharma Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesConway (Guangzhou) Biotechnology Co LtdIriSys LLCCanWell Pharma Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursBreast Carcinoma In SituCarcinoma, Intraductal, Noninfiltrating
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A